A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

Neuroscience

Volumn 240, Issue , 2013, Pages 191-203

  Martin, H L ^a   Mounsey, R B ^a   Sathe, K ^a   Mustafa, S ^a   Nelson, M C ^b   Evans, R M ^b   Teismann, P ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

MPP+; MPTP; Neurodegeneration; Neuroinflammation; PPAR delta; SH SY5Y

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL LOSS; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; FETUS; GENETIC MANIPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CELL COUNT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MACROPHAGE-1 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PPAR DELTA; RATS; SULFONES; THIAZOLES; THIOPHENES; TYROSINE 3-MONOOXYGENASE;

EID: 84876383781     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.02.058     Document Type: Article

References (50)

1. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., Boland R., Evans R.M. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 2002, 99:303-308.
2. Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P., Wahlii W. Peroxisome proliferator-activated receptor β regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J Biol Chem 1999, 274:35881-35888.
3. Bishop-Bailey D., Bystrom J. Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacol Ther 2009, 124:141-150.
4. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002, 82:615-624.
5. Chen M.F., Niggeweg R., Iaizzo P.A., Lehmann-Horn F., Jockusch H. Chloride conductance in mouse muscle is subject to post-transcriptional compensation of the functional Cl - channel 1 gene dosage. J Physiol 1997, 504:75-81.
6. Chen G., Gharib T.G., Huang C.C., Taylor J.M., Misek D.E., Kardia S.L., Giordano T.J., Iannettoni M.D., Orringer M.B., Hanash S.M., Beer D.G. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002, 1:304-313.
7. Chopra B., Hinley J., Oleksiewicz M.B., Southgat J. Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues. Toxicol Pathol 2008, 36:485-495.
8. Ciesielska A., Joniec I., Kurkowska-Jastrzebska I., Cudna A., Przybyłkowski A., Członkowska A., Członkowski A. The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm Res 2009, 58:747-753.
9. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996, 5:137-143.
10. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
11. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκb and iNOS activation. J Neurochem 2004, 88:494-501.
12. Delerive P., Fruchart J., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453-459.
13. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
14. 4 pathway to inflammation control. Nature 1996, 384:39-43.
15. Dong Y., Benveniste E.N. Immune functions of astrocytes. Glia 2001, 36:180-190.
16. Escribano L., Simón A., Pérez-Mediavilla A., Salazar-Colocho P., Río J.D., Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009, 379:406-410.
17. Hébert G., Arsaut J., Dantzer R., Demotes-Mainard J. Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett 2003, 349:191-195.
18. +-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 2011, 384:157-167.
19. Iwashita A., Murmatsu Y., Yamazaki T., Muramoto M., Kita Y., Yamazaki S., Mihara K., Monguchi A., Matsuka N. Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo. J Exp Pharmacol Ther 2007, 320:1087-1096.
20. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2:141-151.
21. Kalinin S., Richardson J.C., Feinstein D.L. A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 2009, 6:431-437.
22. Kreisler A., Gele P., Wiart J., Lhermitte M., Destee A., Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 2007, 1135:77-84.
23. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009, 89:277-287.
24. Luquet S., Gaudel C., Holst D., Lopez-Soriano J., Jehl-Pietri C., Fredenrich A., Grimaldi P.A. Roles of PPAR delta in liquid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta 2005, 1740:313-317.
25. Martin H.L., Mounsey R.B., Mustafa S., Sathe K., Teismann P. Pharmacological manipulation of peroxisome-proliferator activated receptor γ reveals a role of anti-oxidant protection in a model of parkinsonism. Exp Neurol 2012, 235:528-538.
26. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
27. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor α are elevated in the brain from parkinsonian patients. Neurosci Lett 1994, 180:147-150.
28. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor α (TNFα) increases in both the brain and in the CSF from parkinsonian patients. Neurosci Lett 1994, 165:210.
29. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor agonist. J Neurosci 2008, 28:9287-9296.
30. Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., Onoé K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ. J Neuroimmunol 2001, 116:40-48.
31. Nuber S., Petrasch-Parwez E., Winner B., Winkler J., von Hörsten S., Schmidt T., Boy J., Kuhn M., Nguyen H.P., Teismann P., Schulz J.B., Neumann M., Pichler B.J., Reischl G., Holzmann C., Schmitt I., Bornemann A., Kuhn W., Zimmermann F., Servadio A., Riess O. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 2008, 28:2471-2484.
32. Pascal L.E., True L.D., Campbell D.S., Deutsch E.W., Risk M., Coleman I.R., Eichner L.J., Nelson P.S., Liu A.Y. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008, 9:246.
33. Polak P.E., Kalinin S., Russo C.D., Gavrilyuk V., Sharp A., Peters J.M., Richardson J., Willson T.M., Weinberg G., Feinstein D.L. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 168:65-75.
34. Ricote M., Huang J.T., Welch J.S., Glass C.K. The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999, 66:733-739.
35. Santos M.J., Quintanilla R.A., Toro A., Grandy R., Dinamarca M.C., Godoy J.A., Inestrosa N.C. Peroxisomal proliferation protects from β-amyloid neurodegeneration. J Biol Chem 2005, 280:41057-41068.
36. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009, 29:954-963.
37. Shearer B.G., Steger D.J., Way J.M., Stanley T.B., Lobe D.C., Grillot D.A., Iannone M.A., Lazar M.A., Willson T.M., Billin A.N. Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol 2008, 22:523-529.
38. Shi Y., Hon M., Evans R.M. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 2002, 99:2613-2618.
39. Storer P.D., Xu J., Chavis J., Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005, 161:113-122.
40. Sznaidman M.L., Haffner C.D., Maloney P.R., Fivush A., Chao E., Goreham D., Sierra M.L., LeGrumelec C., Xu H.E., Montana V.G., Lambert M.H., Willson T.M., Oliver W.R., Sternbach D.D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) - synthesis and biological activity. Bioorg Med Chem Lett 2003, 13:1517-1521.
41. 2Cl cotransporter gene. J Am Soc Nephrol 2002, 13:604-610.
42. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003, 100:5473-5478.
43. Tian Q., Stepaniants S.B., Mao M., Weng L., Feetham M.C., Doyle M.J., Yi E.C., Dai H., Thorsson V., Eng J., Goodlett D., Berger J.P., Gunter B., Linseley P.S., Stoughton R.B., Aebersold R., Collins S.J., Hanlon W.A., Hood W.E. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004, 3:960-969.
44. Wang H., Xie H., Sun X., Tranguch S., Zhang H., Jia X., Wang D., Das S.K., Desvergne B., Wahli W., DuBois R.N., Dey S.K. Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success. J Biol Chem 2007, 282:37770-37782.
45. West M.J. New stereological methods for counting neurons. Neurobiol Aging 1993, 14:275-285.
46. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
47. Xu J., Storer P.D., Chavis J.A., Racke M.K., Drew P.D. Agonists for the peroxisome proliferator-activated receptor α and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 2005, 81:403-411.
48. Xu J., Chavis J.A., Racke M.K., Drew P.D. Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006, 176:95-105.
49. Yacoub N., Romanowska M., Krauss S., Schweiger S., Foerster J. PPARδ is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 2008, 128:1940-1949.
50. Yi J., Park S., Brooks N., Lang B.T., Vemuganti R. PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidant mechanisms. Brain Res 2008, 1244:164-172.